DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 211155

Email this page to a colleague

« Back to Dashboard

NDA 211155 describes COPIKTRA, which is a drug marketed by Verastem Inc and is included in one NDA. There are four patents protecting this drug. Additional details are available on the COPIKTRA profile page.

The generic ingredient in COPIKTRA is duvelisib. Additional details are available on the duvelisib profile page.

Summary for 211155

Tradename:	COPIKTRA
Applicant:	Verastem Inc
Ingredient:	duvelisib
Patents:	4

Generic Entry Opportunity Date for 211155

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) AFTER AT LEAST TWO PRIOR THERAPIES

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	CAPSULE;ORAL			Strength	15MG
Approval Date:	Sep 24, 2018	TE:		RLD:	Yes
Regulatory Exclusivity Expiration:	Sep 24, 2023
Regulatory Exclusivity Use:	NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:	Sep 24, 2025
Regulatory Exclusivity Use:	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) AFTER AT LEAST TWO PRIOR THERAPIES
Regulatory Exclusivity Expiration:	Sep 24, 2025
Regulatory Exclusivity Use:	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) AFTER AT LEAST TWO PRIOR SYSTEMIC THERAPIES

Complete Access Available with Subscription